Search - tctmd.com

Displaying 201 - 220 of 469

Sort: Relevancy | Date

Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54

Presentation

Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54

September 12, 2017

Validation of the European Society of Cardiology 0/1-Hour Algorithm for Rule-out and Rule-in of Acute Myocardial Infarction

Presentation ESC 2017

Validation of the European Society of Cardiology 0/1-Hour Algorithm for Rule-out and Rule-in of Acute Myocardial Infarction

Presenter: Raphael Twerenbold

September 08, 2017

Acute MI Mortality Has Dropped to Very Low Levels in France

News Conference News ESC 2017

Acute MI Mortality Has Dropped to Very Low Levels in France

September 08, 2017

No More Absorb BVS: Abbott Puts a Stop to Sales

News Daily News

No More Absorb BVS: Abbott Puts a Stop to Sales

September 08, 2017

ESC Algorithm for Rapidly Diagnosing NSTEMI Works, Study Confirms

News Conference News ESC 2017

ESC Algorithm for Rapidly Diagnosing NSTEMI Works, Study Confirms

September 08, 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

September 07, 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

News Conference News ESC 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

September 01, 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

News Conference News ESC 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

September 01, 2017

TCTMD’s Top 10 Most Popular Stories for August 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

August 31, 2017

NSTEACS: Risk Stratification and Treatment

Presentation iASSESS 2017

NSTEACS: Risk Stratification and Treatment

Presenter: Dmitriy N. Feldman

August 30, 2017

Radial Access and Related Complications

Presentation iASSESS 2017

Radial Access and Related Complications

Presenter: Jordan Safirstein

August 30, 2017

Complex PCI II: CTO and SVG

Presentation iASSESS 2017

Complex PCI II: CTO and SVG

Presenter: Kevin Croce

August 30, 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Presentation ESC 2017

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Presenter: Anselm K. Gitt

August 30, 2017

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in those Undergoing PCI

Presentation iASSESS 2017

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in those Undergoing PCI

Presenter: Sripal Bangalore

August 30, 2017

Top Stories in Cardiology, August 2017

Podcast Heart Sounds

Top Stories in Cardiology, August 2017

August 30, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Spontaneous Coronary Artery Dissection: Clinical Outcomes and Risk of Recurrence

Presentation

Spontaneous Coronary Artery Dissection: Clinical Outcomes and Risk of Recurrence

August 29, 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

News Conference News ESC 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

August 29, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.